What amount sold does Palimpsest Bio Corp. report in Form D filings?

The latest linked filings report $172K sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Palimpsest Bio Corp.'s most recent SEC filing?

Palimpsest Bio Corp.'s most recent Form D filing was on 2026-10-30.

How many investors does Palimpsest Bio Corp. have?

The most recent Form D filing lists 4 investor(s).

Palimpsest Bio Corp.

CIK: 0002162952·Biotechnology·Las Vegas, NV·Corporation·Founded 2026

Reported Sold

$172,000

Total Filings

Identified Offerings

Last Filed

Oct 30, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Oct 30, 2026Form D — New notice

Reported sold: $172,000 · Target: $1,000,000

Rule 506(b)·4 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

No Revenues

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$172,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Matthew Davin Korpela

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Oct 30, 2026	New	$1,000,000	$172,000	4

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

511 Therapeutics, Inc.

Biotechnology

Offering target: $1,000,000

Filed Oct 30, 2026